Isradipine: Difference between revisions
No edit summary |
m (Protected "Isradipine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
(22 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
|authorTag={{SS}} | |authorTag={{SS}}; {{TA}} | ||
|genericName=Isradipine | |genericName=Isradipine | ||
|aOrAn=a | |aOrAn=a | ||
|drugClass=Calcium Channel Blocker | |drugClass=Calcium Channel Blocker | ||
|indicationType=treatment | |||
|indication=[[hypertension]] | |indication=[[hypertension]] | ||
|adverseReactions=[[peripheral edema]], [[flushing]], [[dizziness]], [[headache]], [[fatigue]] | |adverseReactions=[[peripheral edema]], [[flushing]], [[dizziness]], [[headache]], [[fatigue]] | ||
Line 11: | Line 12: | ||
* The dosage of isradipine should be individualized. | * The dosage of isradipine should be individualized. | ||
* Initial dose: '''2.5 mg b.i.d'''. alone or in combination with a thiazide diuretic. | * Initial dose: '''2.5 mg b.i.d'''. alone or in combination with a [[thiazide diuretic]]. | ||
::* An antihypertensive response usually occurs within 2-3 hours. Maximal response may require 2-4 weeks. | ::* An antihypertensive response usually occurs within 2-3 hours. Maximal response may require 2-4 weeks. | ||
::* If a satisfactory reduction in blood pressure does not occur after this period, the dose may be adjusted in increments of '''5 mg/day''' at 2-4 week intervals up to a maximum of '''20 mg/day'''. | ::* If a satisfactory reduction in blood pressure does not occur after this period, the dose may be adjusted in increments of '''5 mg/day''' at 2-4 week intervals up to a maximum of '''20 mg/day'''. | ||
::* Most patients, however, show no additional response to doses above 10 mg/day, and adverse effects are increased in frequency above 10 mg/day. | ::* Most patients, however, show no additional response to doses above 10 mg/day, and adverse effects are increased in frequency above 10 mg/day. | ||
* The bioavailability of isradipine (increased AUC) is increased in elderly patients (above 65 years of age), patients with hepatic functional impairment, and patients with mild renal impairment. Ordinarily, the starting dose should still be '''2.5 mg b.i.d'''. in these patients. | * The bioavailability of isradipine (increased AUC) is increased in elderly patients (above 65 years of age), patients with [[Hepatic failure|hepatic functional impairment]], and patients with mild renal impairment. Ordinarily, the starting dose should still be '''2.5 mg b.i.d'''. in these patients. | ||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isradipine sandbox in adult patients. | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isradipine sandbox in adult patients. | ||
|offLabelAdultNoGuideSupport=<H4>[[Angina]]</H4> | |offLabelAdultNoGuideSupport=<H4>[[Angina]]</H4> | ||
Line 24: | Line 25: | ||
:* '''7.5 mg''' <ref name="pmid2949583">{{cite journal| author=Taylor SH, Jackson NC, Allen J, Pool PE| title=Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris. | journal=Am J Cardiol | year= 1987 | volume= 59 | issue= 3 | pages= 123B-129B | pmid=2949583 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2949583 }} </ref> | :* '''7.5 mg''' <ref name="pmid2949583">{{cite journal| author=Taylor SH, Jackson NC, Allen J, Pool PE| title=Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris. | journal=Am J Cardiol | year= 1987 | volume= 59 | issue= 3 | pages= 123B-129B | pmid=2949583 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2949583 }} </ref> | ||
:* '''2.5-7.5 mg PO tid''' <ref name="pmid2565689">{{cite journal| author=Rüegg PC, Nelson DJ| title=Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris. | journal=Am J Med | year= 1989 | volume= 86 | issue= 4A | pages= 70-4 | pmid=2565689 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2565689 }} </ref> | :* '''2.5-7.5 mg PO tid''' <ref name="pmid2565689">{{cite journal| author=Rüegg PC, Nelson DJ| title=Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris. | journal=Am J Med | year= 1989 | volume= 86 | issue= 4A | pages= 70-4 | pmid=2565689 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2565689 }} </ref> | ||
|fdaLIADPed=FDA Package Insert for Isradipine contains no information regarding FDA-labeled indications and dosage information for children. | |fdaLIADPed=FDA Package Insert for Isradipine contains no information regarding FDA-labeled indications and dosage information for children. | ||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isradipine sandbox in pediatric patients. | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isradipine sandbox in pediatric patients. | ||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isradipine sandbox in pediatric patients. | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isradipine sandbox in pediatric patients. | ||
|contraindications=Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation | |contraindications=Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation | ||
|warnings= | |warnings=None | ||
None | |||
===PRECAUTIONS=== | ===PRECAUTIONS=== | ||
Line 38: | Line 35: | ||
====General==== | ====General==== | ||
Blood Pressure: Because isradipine decreases peripheral resistance, like other [[calcium blockers]] isradipine may occasionally produce symptomatic [[hypotension]]. However, symptoms like [[syncope]] and severe [[dizziness]] have rarely been reported in hypertensive patients administered isradipine, particularly at the initial recommended doses | Blood Pressure: Because isradipine decreases peripheral resistance, like other [[calcium blockers]] isradipine may occasionally produce symptomatic [[hypotension]]. However, symptoms like [[syncope]] and severe [[dizziness]] have rarely been reported in hypertensive patients administered isradipine, particularly at the initial recommended doses. | ||
Use in Patients with [[Congestive Heart Failure]]: Although acute hemodynamic studies in patients with [[congestive heart failure]] have shown that isradipine reduced afterload without impairing myocardial contractility, it has a negative inotropic effect at high doses in vitro and possibly in some patients. Caution should be exercised when using isradipine in [[congestive heart failure]] patients, particularly in combination with a [[beta-blocker]]. | Use in Patients with [[Congestive Heart Failure]]: Although acute hemodynamic studies in patients with [[congestive heart failure]] have shown that isradipine reduced afterload without impairing myocardial contractility, it has a negative inotropic effect at high doses in vitro and possibly in some patients. Caution should be exercised when using isradipine in [[congestive heart failure]] patients, particularly in combination with a [[beta-blocker]]. | ||
|clinicalTrials=In multiple dose U.S. studies in hypertension, 1228 patients received isradipine alone or in combination with other agents, principally a thiazide diuretic, 934 of them in controlled comparisons with placebo or active agents. An additional 652 patients (which includes 374 normal volunteers) received isradipine in U.S. studies of conditions other than hypertension, and 1321 patients received isradipine in non-U.S. studies. About 500 patients received isradipine in long-term hypertension studies, 410 of them for at least 6 months. The adverse reaction rates given below are principally based on controlled hypertension studies, but rarer serious events are derived from all exposures to isradipine, including foreign marketing experience. | |clinicalTrials=In multiple dose U.S. studies in hypertension, 1228 patients received isradipine alone or in combination with other agents, principally a thiazide diuretic, 934 of them in controlled comparisons with placebo or active agents. An additional 652 patients (which includes 374 normal volunteers) received isradipine in U.S. studies of conditions other than hypertension, and 1321 patients received isradipine in non-U.S. studies. About 500 patients received isradipine in long-term hypertension studies, 410 of them for at least 6 months. The adverse reaction rates given below are principally based on controlled hypertension studies, but rarer serious events are derived from all exposures to isradipine, including foreign marketing experience. | ||
Most adverse reactions were mild and related to the vasodilatory effects of isradipine (dizziness, edema, palpitations, flushing, tachycardia), and many were transient. About 5% of isradipine patients left studies prematurely because of adverse reactions (vs. 3% of placebo patients and 6% of active control patients), principally due to headache, edema, dizziness, palpitations, and gastrointestinal disturbances. | Most adverse reactions were mild and related to the vasodilatory effects of isradipine ([[dizziness]], [[edema]], [[palpitations]], [[flushing]], [[tachycardia]]), and many were transient. About 5% of isradipine patients left studies prematurely because of adverse reactions (vs. 3% of placebo patients and 6% of active control patients), principally due to [[headache]], [[edema]], [[dizziness]], [[palpitations]], and gastrointestinal disturbances. | ||
The following table shows the most common adverse reactions, volunteered or elicited, considered by the investigator to be at least possibly drug related. The results for the isradipine treated patients are presented for all doses pooled together (reported by 1% or greater of patients receiving any dose of isradipine), and also for the two treatment regimens most applicable to the treatment of hypertension with isradipine: (1) initial and maintenance dose of 2.5 mg b.i.d., and (2) initial dose of 2.5 mg b.i.d. followed by maintenance dose of 5 mg b.i.d. | The following table shows the most common adverse reactions, volunteered or elicited, considered by the investigator to be at least possibly drug related. The results for the isradipine treated patients are presented for all doses pooled together (reported by 1% or greater of patients receiving any dose of isradipine), and also for the two treatment regimens most applicable to the treatment of [[hypertension]] with isradipine: (1) initial and maintenance dose of 2.5 mg b.i.d., and (2) initial dose of 2.5 mg b.i.d. followed by maintenance dose of 5 mg b.i.d. | ||
[[File:Isradipine01.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | [[File:Isradipine01.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | ||
Line 53: | Line 50: | ||
<sup>*</sup><small><small><small>Propranolol, prazosin, hydrochlorothiazide, enalapril, captopril.</small></small></small> | <sup>*</sup><small><small><small>Propranolol, prazosin, hydrochlorothiazide, enalapril, captopril.</small></small></small> | ||
Except for headache, which is not clearly drug-related (see previous table), the more frequent adverse reactions listed show little change, or increase slightly, in frequency over time, as shown in the following table:]] | Except for [[headache]], which is not clearly drug-related (see previous table), the more frequent adverse reactions listed show little change, or increase slightly, in frequency over time, as shown in the following table:]] | ||
[[File:Isradipine02.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | [[File:Isradipine02.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | ||
Line 63: | Line 60: | ||
The following adverse experiences were reported in 0.5%-1% of the isradipine-treated patients in hypertensive studies, or are rare. More serious events from this and other data sources, including postmarketing exposure, are shown in italics. The relationship of these adverse events to isradipine administration is uncertain. | The following adverse experiences were reported in 0.5%-1% of the isradipine-treated patients in hypertensive studies, or are rare. More serious events from this and other data sources, including postmarketing exposure, are shown in italics. The relationship of these adverse events to isradipine administration is uncertain. | ||
'''Skin''': [[pruritus]], [[urticaria]] | '''Skin''': [[pruritus]], [[urticaria]]. | ||
'''Musculoskeletal''': cramps of legs/feet | '''Musculoskeletal''': cramps of legs/feet. | ||
'''Respiratory''': [[cough]] | '''Respiratory''': [[cough]]. | ||
'''Cardiovascular''': shortness of breath, [[hypotension]], [[atrial fibrillation]], [[ventricular fibrillation]], [[myocardial infarction]], [[heart failure]] | '''Cardiovascular''': shortness of breath, [[hypotension]], [[atrial fibrillation]], [[ventricular fibrillation]], [[myocardial infarction]], [[heart failure]]. | ||
'''Gastrointestinal''': abdominal discomfort, [[constipation]], [[diarrhea]] | '''Gastrointestinal''': abdominal discomfort, [[constipation]], [[diarrhea]]. | ||
'''Urogenital''': [[nocturia]] | '''Urogenital''': [[nocturia]]. | ||
'''Nervous System''': [[drowsiness]], [[insomnia]], [[lethargy]], [[nervousness]], [[impotence]], decreased libido, [[ depression]], [[syncope]], [[paresthesia]] (which includes numbness and tingling),[[transient ischemic attack]], [[stroke]] | '''Nervous System''': [[drowsiness]], [[insomnia]], [[lethargy]], [[nervousness]], [[impotence]], decreased libido, [[ depression]], [[syncope]], [[paresthesia]] (which includes numbness and tingling),[[transient ischemic attack]], [[stroke]]. | ||
'''Autonomic''': [[hyperhidrosis]], visual disturbance, dry mouth, [[numbness]] | '''Autonomic''': [[hyperhidrosis]], [[visual disturbance]], [[dry mouth]], [[numbness]]. | ||
'''Miscellaneous''': throat discomfort, [[leukopenia]], elevated liver function tests. | '''Miscellaneous''': throat discomfort, [[leukopenia]], elevated [[liver function tests]]. | ||
|postmarketing=FDA Package Insert for Isradipine contains no information regarding postmarketing experience. | |postmarketing=FDA Package Insert for Isradipine contains no information regarding postmarketing experience. | ||
|drugInteractions='''Nitroglycerin''': Isradipine has been safely coadministered with [[nitroglycerin]]. | |drugInteractions='''Nitroglycerin''': Isradipine has been safely coadministered with [[nitroglycerin]]. | ||
Line 85: | Line 82: | ||
'''Hydrochlorothiazide''': A study in normal healthy volunteers has shown that concomitant administration of isradipine and [[hydrochlorothiazide]] does not result in altered pharmacokinetics of either drug. In a study in hypertensive patients, addition of isradipine to existing [[hydrochlorothiazide]] therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. | '''Hydrochlorothiazide''': A study in normal healthy volunteers has shown that concomitant administration of isradipine and [[hydrochlorothiazide]] does not result in altered pharmacokinetics of either drug. In a study in hypertensive patients, addition of isradipine to existing [[hydrochlorothiazide]] therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. | ||
'''Propranolol''': In a single dose study in normal volunteers, co-administration of [[propranolol]] had a small effect on the rate but no effect on the extent of isradipine bioavailability. Significant increases in AUC (27%) and Cmax (58%) and decreases in tmax (23%) of [[propranolol]] were noted in this study. However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d. [[propranolol]] to healthy volunteers under steady-state conditions had no relevant effect on either drug’s bioavailability. AUC and Cmax differences were <20% between isradipine given singly and in combination with [[propranolol]], and between [[propranolol]] given singly and in combination with isradipine. | '''Propranolol''': In a single dose study in normal volunteers, co-administration of [[propranolol]] had a small effect on the rate but no effect on the extent of isradipine [[bioavailability]]. Significant increases in AUC (27%) and Cmax (58%) and decreases in tmax (23%) of [[propranolol]] were noted in this study. However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d. [[propranolol]] to healthy volunteers under steady-state conditions had no relevant effect on either drug’s [[bioavailability]]. AUC and Cmax differences were <20% between isradipine given singly and in combination with [[propranolol]], and between [[propranolol]] given singly and in combination with isradipine. | ||
'''Cimetidine''': In a study in healthy volunteers, a one-week course of [[cimetidine]] at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%). If isradipine therapy is initiated in a patient currently receiving cimetidine, careful monitoring for adverse reactions is advised and downward dose adjustment may be required. | '''Cimetidine''': In a study in healthy volunteers, a one-week course of [[cimetidine]] at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%). If isradipine therapy is initiated in a patient currently receiving cimetidine, careful monitoring for adverse reactions is advised and downward dose adjustment may be required. | ||
Line 97: | Line 94: | ||
'''Fentanyl Anesthesia''': Severe [[hypotension]] has been reported during fentanyl anesthesia with concomitant use of a [[beta-blocker]] and a [[calcium channel blocker]]. Even though such interactions have not been seen in clinical studies with isradipine, an increased volume of circulating fluids might be required if such an interaction were to occur. | '''Fentanyl Anesthesia''': Severe [[hypotension]] has been reported during fentanyl anesthesia with concomitant use of a [[beta-blocker]] and a [[calcium channel blocker]]. Even though such interactions have not been seen in clinical studies with isradipine, an increased volume of circulating fluids might be required if such an interaction were to occur. | ||
|FDAPregCat=C | |FDAPregCat=C | ||
|useInPregnancyFDA=Isradipine was administered orally to rats and rabbits during organogenesis. Treatment of pregnant rats with doses of 6, 20, or 60 mg/kg/day produced a significant reduction in maternal weight gain during treatment with the highest dose (150 times the maximum recommended human daily dose) but with no lasting effects on the mother or the offspring. Treatment of pregnant rabbits with doses of 1, 3, or 10 mg/kg/day (2.5, 7.5, and 25 times the maximum recommended human daily dose) produced decrements in maternal body weight gain and increased fetal resorption at the two higher doses. There was no evidence of embryotoxicity at doses which were not maternotoxic and no evidence of teratogenicity at any dose tested. In a peri/postnatal administration study in rats, reduced maternal body weight gain during late pregnancy at oral doses of 20 and 60 mg/kg/day isradipine was associated with reduced birth weights and decreased peri and postnatal pup survival. | |useInPregnancyFDA=Isradipine was administered orally to rats and rabbits during [[organogenesis]]. Treatment of pregnant rats with doses of 6, 20, or 60 mg/kg/day produced a significant reduction in maternal weight gain during treatment with the highest dose (150 times the maximum recommended human daily dose) but with no lasting effects on the mother or the offspring. Treatment of pregnant rabbits with doses of 1, 3, or 10 mg/kg/day (2.5, 7.5, and 25 times the maximum recommended human daily dose) produced decrements in maternal body weight gain and increased fetal resorption at the two higher doses. There was no evidence of embryotoxicity at doses which were not maternotoxic and no evidence of teratogenicity at any dose tested. In a peri/postnatal administration study in rats, reduced maternal body weight gain during late pregnancy at oral doses of 20 and 60 mg/kg/day isradipine was associated with reduced birth weights and decreased peri and postnatal pup survival. | ||
There are no adequate and well controlled studies in pregnant women. The use of isradipine during pregnancy should only be considered if the potential benefit outweighs potential risks. | There are no adequate and well controlled studies in pregnant women. The use of isradipine during pregnancy should only be considered if the potential benefit outweighs potential risks. | ||
Line 109: | Line 106: | ||
Available data suggest that, as with other [[dihydropyridines]], overdosage with isradipine might result in excessive peripheral vasodilation with subsequent marked and probably prolonged systemic [[hypotension]], and [[tachycardia]]. Emesis, gastric lavage, administration of activated charcoal followed in 30 minutes by a saline cathartic would be reasonable therapy. Isradipine is highly protein-bound and not removed by [[hemodialysis]]. Overdosage characterized by clinically significant [[hypotension ]]should be treated with active cardiovascular support including monitoring of cardiac and respiratory function, elevation of lower extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor (such as [[epinephrine]], [[norepinephrine]], or [[levarterenol]]) may be helpful in restoring a normotensive state, provided that there is no contraindication to its use. | Available data suggest that, as with other [[dihydropyridines]], overdosage with isradipine might result in excessive peripheral vasodilation with subsequent marked and probably prolonged systemic [[hypotension]], and [[tachycardia]]. Emesis, gastric lavage, administration of activated charcoal followed in 30 minutes by a saline cathartic would be reasonable therapy. Isradipine is highly protein-bound and not removed by [[hemodialysis]]. Overdosage characterized by clinically significant [[hypotension ]]should be treated with active cardiovascular support including monitoring of cardiac and respiratory function, elevation of lower extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor (such as [[epinephrine]], [[norepinephrine]], or [[levarterenol]]) may be helpful in restoring a normotensive state, provided that there is no contraindication to its use. | ||
Refractory [[hypotension ]]or AV conduction disturbances may be treated with intravenous calcium salts, or glucagon. Cimetidine should be withheld in such instances due to the risk of further increasing plasma isradipine levels. | Refractory [[hypotension ]]or AV conduction disturbances may be treated with intravenous calcium salts, or [[glucagon]]. [[Cimetidine]] should be withheld in such instances due to the risk of further increasing plasma isradipine levels. | ||
Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival. | Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival. | ||
Line 182: | Line 179: | ||
Inactive Ingredients: colloidal silicon dioxide, red iron oxide (2.5 mg capsule only, yellow iron oxide, gelatin, anhydrous lactose, magnesium stearate, sodium lauryl sulfate, starch (corn), titanium dioxide, black ink: black iron oxide, shellac and potassium hydroxide. | Inactive Ingredients: colloidal silicon dioxide, red iron oxide (2.5 mg capsule only, yellow iron oxide, gelatin, anhydrous lactose, magnesium stearate, sodium lauryl sulfate, starch (corn), titanium dioxide, black ink: black iron oxide, shellac and potassium hydroxide. | ||
|PD=In man, peripheral vasodilation produced by isradipine is reflected by decreased systemic vascular resistance and increased cardiac output. Hemodynamic studies conducted in patients with normal left ventricular function produced, following intravenous isradipine administration, increases in cardiac index, [[stroke]] volume index, coronary sinus blood flow, heart rate and peak positive left ventricular dP/dt. Systemic, coronary, and pulmonary vascular resistance was decreased. These studies were conducted with doses of isradipine which produced clinically significant decreases in blood pressure. The clinical consequences of these hemodynamic effects, if any, have not been evaluated. | |PD=In man, peripheral vasodilation produced by isradipine is reflected by decreased [[systemic vascular resistance]] and increased [[cardiac output]]. Hemodynamic studies conducted in patients with normal [[left ventricular function]] produced, following intravenous isradipine administration, increases in [[cardiac index]], [[stroke]] volume index, coronary sinus blood flow, heart rate and peak positive left ventricular dP/dt. Systemic, coronary, and pulmonary vascular resistance was decreased. These studies were conducted with doses of isradipine which produced clinically significant decreases in blood pressure. The clinical consequences of these hemodynamic effects, if any, have not been evaluated. | ||
Effects on heart rate are variable, dependent upon rate of administration and presence of underlying cardiac condition. While increases in both peak positive dP/dt and LV ejection fraction are seen when intravenous isradipine is given, it is impossible to conclude that these represent a positive inotropic effect due to simultaneous changes in preload and afterload. In patients with coronary artery disease undergoing atrial pacing during cardiac catheterization, intravenous isradipine diminished abnormalities of systolic performance. In patients with moderate left ventricular dysfunction, oral and intravenous isradipine in doses which reduce blood pressure by 12% to 30%, resulted in improvement in cardiac index without increase in heart rate, and with no change or reduction in pulmonary capillary wedge pressure. Combination of isradipine and propranolol did not significantly affect left ventricular dP/dt max. The clinical consequences of these effects have not been evaluated. | Effects on heart rate are variable, dependent upon rate of administration and presence of underlying cardiac condition. While increases in both peak positive dP/dt and LV ejection fraction are seen when intravenous isradipine is given, it is impossible to conclude that these represent a positive inotropic effect due to simultaneous changes in preload and afterload. In patients with coronary artery disease undergoing atrial pacing during cardiac catheterization, intravenous isradipine diminished abnormalities of systolic performance. In patients with moderate [[left ventricular dysfunction]], oral and intravenous isradipine in doses which reduce blood pressure by 12% to 30%, resulted in improvement in cardiac index without increase in heart rate, and with no change or reduction in pulmonary capillary wedge pressure. Combination of isradipine and propranolol did not significantly affect left ventricular dP/dt max. The clinical consequences of these effects have not been evaluated. | ||
|PK=sradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%. Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5-20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration. Administration of isradipine with food significantly increases the time to peak by about an hour, but has no effect on the total bioavailability (area under the curve) of the drug. Isradipine is 95% bound to plasma proteins. Both peak plasma concentration and AUC exhibit a linear relationship to dose over the 0-20 mg dose range. The elimination of isradipine is biphasic with an early half-life of 1 ½-2 hours, and a terminal half-life of about 8 hours. The total body clearance of isradipine is 1.4 L/min and the apparent volume od disturbance is 3 L/kg. | |PK=sradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a [[bioavailability]] of about 15%-24%. Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5-20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration. Administration of isradipine with food significantly increases the time to peak by about an hour, but has no effect on the total bioavailability (area under the curve) of the drug. Isradipine is 95% bound to plasma proteins. Both peak plasma concentration and AUC exhibit a linear relationship to dose over the 0-20 mg dose range. The elimination of isradipine is biphasic with an early half-life of 1 ½-2 hours, and a terminal half-life of about 8 hours. The total body clearance of isradipine is 1.4 L/min and the apparent volume od disturbance is 3 L/kg. | ||
Isradipine is completely metabolized prior to excretion, and no unchanged drug is detected in the urine. Six metabolites have been characterized in blood and urine, with the mono acids of the pyridine derivative and a cyclic lactone product accounting for >75% fo the material identified. Approximately 60%-65% of an administered dose is excreted in the urine and 25%-30% in the feces. Mild [[renal impairment]] (creatinine clearance 30 to 80 mL/min) increases the bioavailability (AUC) of isradipine by 45%. Progressive deterioration reverses this trend, and patients with severe [[renal failure]] (creatinine clearance <10 mL/min) who have been on [[hemodialysis]] show a 20% to 50% lower AUC than healthy volunteers. No pharmacokinetic information is available in drug therapy during [[hemodialysis]]. In elderly patients Cmax and AUC are increased by 13% and 40%, respectively; in patients with hepatic impairment, Cmax and AUC are increased by 32% and 52%, respectively | Isradipine is completely metabolized prior to excretion, and no unchanged drug is detected in the urine. Six metabolites have been characterized in blood and urine, with the mono acids of the pyridine derivative and a cyclic lactone product accounting for >75% fo the material identified. Approximately 60%-65% of an administered dose is excreted in the urine and 25%-30% in the feces. Mild [[renal impairment]] (creatinine clearance 30 to 80 mL/min) increases the bioavailability (AUC) of isradipine by 45%. Progressive deterioration reverses this trend, and patients with severe [[renal failure]] (creatinine clearance <10 mL/min) who have been on [[hemodialysis]] show a 20% to 50% lower AUC than healthy volunteers. No pharmacokinetic information is available in drug therapy during [[hemodialysis]]. In elderly patients Cmax and AUC are increased by 13% and 40%, respectively; in patients with [[hepatic impairment]], Cmax and AUC are increased by 32% and 52%, respectively. | ||
===Electrophysiologic Effects=== | ===Electrophysiologic Effects=== | ||
Line 193: | Line 190: | ||
In general, no detrimental effects on the cardiac conduction system were seen with the use of isradipine. Electrophysiologic studies were conducted on patients with normal sinus and atrioventricular node function. Intravenous isradipine in doses which reduce systolic blood pressure did not affect PR, QRS, AH* or HV* intervals. | In general, no detrimental effects on the cardiac conduction system were seen with the use of isradipine. Electrophysiologic studies were conducted on patients with normal sinus and atrioventricular node function. Intravenous isradipine in doses which reduce systolic blood pressure did not affect PR, QRS, AH* or HV* intervals. | ||
No changes were seen in Wenckebach cycle length, atrial, and ventricular refractory periods. Slight prolongation of QTc interval of 3% was seen in one study. Effects on sinus node recovery time (CSNRT) were mild or not seen. | No changes were seen in Wenckebach cycle length, atrial, and ventricular refractory periods. Slight [[QT prolongation|prolongation of QTc interval]] of 3% was seen in one study. Effects on sinus node recovery time (CSNRT) were mild or not seen. | ||
In patients with sick sinus syndrome, at doses which significantly reduced blood pressure, intravenous isradipine resulted in no depressant effect on sinus and atrioventricular node function. | In patients with sick sinus syndrome, at doses which significantly reduced blood pressure, intravenous isradipine resulted in no depressant effect on sinus and atrioventricular node function. | ||
Line 205: | Line 202: | ||
Isradipine Capsules, USP 5 mg are Filled Gelatin Capsules Size #3, Cap: Flesh Opaque/Body: Flesh Opaque with Imprint "A-264" on cap and body. Available in bottles of 100's and 500's. | Isradipine Capsules, USP 5 mg are Filled Gelatin Capsules Size #3, Cap: Flesh Opaque/Body: Flesh Opaque with Imprint "A-264" on cap and body. Available in bottles of 100's and 500's. | ||
|storage=Store 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure as required. | |storage=Store 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure as required. | ||
|packLabel=[[File:Isradipine label 01.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:Isradipine label 02.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:Isradipine label 03.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:Isradipine label 04.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:Isradipine panel 01.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:Isradipine panel 02.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
|fdaPatientInfo=FDA Package Insert for Isradipine contains no information regarding Patient Counseling Information. | |fdaPatientInfo=FDA Package Insert for Isradipine contains no information regarding Patient Counseling Information. | ||
|alcohol=Alcohol-Isradipine sandbox interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |alcohol=Alcohol-Isradipine sandbox interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
Line 211: | Line 214: | ||
|lookAlike=Dynacirc - Dynacin<ref name="www.ismp.org">{{Cite web | last = | first = | title =https://www.ismp.org | url = https://www.ismp.org | publisher = | date = | accessdate = }}</ref> | |lookAlike=Dynacirc - Dynacin<ref name="www.ismp.org">{{Cite web | last = | first = | title =https://www.ismp.org | url = https://www.ismp.org | publisher = | date = | accessdate = }}</ref> | ||
}} | }} | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
[[Category:Calcium channel blockers]] | |||
Latest revision as of 16:33, 20 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]; Turky Alkathery, M.D. [3]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Isradipine is a Calcium Channel Blocker that is FDA approved for the treatment of hypertension. Common adverse reactions include peripheral edema, flushing, dizziness, headache, fatigue.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Hypertension
- The dosage of isradipine should be individualized.
- Initial dose: 2.5 mg b.i.d. alone or in combination with a thiazide diuretic.
- An antihypertensive response usually occurs within 2-3 hours. Maximal response may require 2-4 weeks.
- If a satisfactory reduction in blood pressure does not occur after this period, the dose may be adjusted in increments of 5 mg/day at 2-4 week intervals up to a maximum of 20 mg/day.
- Most patients, however, show no additional response to doses above 10 mg/day, and adverse effects are increased in frequency above 10 mg/day.
- The bioavailability of isradipine (increased AUC) is increased in elderly patients (above 65 years of age), patients with hepatic functional impairment, and patients with mild renal impairment. Ordinarily, the starting dose should still be 2.5 mg b.i.d. in these patients.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Isradipine sandbox in adult patients.
Non–Guideline-Supported Use
Angina
- Dosing information
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
FDA Package Insert for Isradipine contains no information regarding FDA-labeled indications and dosage information for children.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Isradipine sandbox in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Isradipine sandbox in pediatric patients.
Contraindications
Isradipine is contraindicated in individuals who have shown hypersensitivity to any of the ingredients in the formulation
Warnings
None
PRECAUTIONS
General
Blood Pressure: Because isradipine decreases peripheral resistance, like other calcium blockers isradipine may occasionally produce symptomatic hypotension. However, symptoms like syncope and severe dizziness have rarely been reported in hypertensive patients administered isradipine, particularly at the initial recommended doses.
Use in Patients with Congestive Heart Failure: Although acute hemodynamic studies in patients with congestive heart failure have shown that isradipine reduced afterload without impairing myocardial contractility, it has a negative inotropic effect at high doses in vitro and possibly in some patients. Caution should be exercised when using isradipine in congestive heart failure patients, particularly in combination with a beta-blocker.
Adverse Reactions
Clinical Trials Experience
In multiple dose U.S. studies in hypertension, 1228 patients received isradipine alone or in combination with other agents, principally a thiazide diuretic, 934 of them in controlled comparisons with placebo or active agents. An additional 652 patients (which includes 374 normal volunteers) received isradipine in U.S. studies of conditions other than hypertension, and 1321 patients received isradipine in non-U.S. studies. About 500 patients received isradipine in long-term hypertension studies, 410 of them for at least 6 months. The adverse reaction rates given below are principally based on controlled hypertension studies, but rarer serious events are derived from all exposures to isradipine, including foreign marketing experience.
Most adverse reactions were mild and related to the vasodilatory effects of isradipine (dizziness, edema, palpitations, flushing, tachycardia), and many were transient. About 5% of isradipine patients left studies prematurely because of adverse reactions (vs. 3% of placebo patients and 6% of active control patients), principally due to headache, edema, dizziness, palpitations, and gastrointestinal disturbances.
The following table shows the most common adverse reactions, volunteered or elicited, considered by the investigator to be at least possibly drug related. The results for the isradipine treated patients are presented for all doses pooled together (reported by 1% or greater of patients receiving any dose of isradipine), and also for the two treatment regimens most applicable to the treatment of hypertension with isradipine: (1) initial and maintenance dose of 2.5 mg b.i.d., and (2) initial dose of 2.5 mg b.i.d. followed by maintenance dose of 5 mg b.i.d.
![](/images/7/7b/Isradipine01.jpg)
†Initial dose of 2.5 mg b.i.d. followed by maintenance dose of 5 mg b.i.d. †† Initial dose of 2.5 mg b.i.d. followed by sequential titration to 5 mg b.i.d., 7.5 mg b.i.d., and maintenance dose of 10 mg b.i.d.
*Propranolol, prazosin, hydrochlorothiazide, enalapril, captopril.
Except for headache, which is not clearly drug-related (see previous table), the more frequent adverse reactions listed show little change, or increase slightly, in frequency over time, as shown in the following table:]]
![](/images/d/dc/Isradipine02.jpg)
Edema, palpitations, fatigue, and flushing appear to be dose-related, especially at the higher doses of 15-20 mg/day.
In open-label, long-term studies of up to two years in duration, the adverse events reported were generally the same as those reported in the short-term controlled trials. The overall frequencies of these adverse events were slightly higher in the long-term than in the controlled studies, but as in the controlled trials most adverse reactions were mild and transient.
The following adverse experiences were reported in 0.5%-1% of the isradipine-treated patients in hypertensive studies, or are rare. More serious events from this and other data sources, including postmarketing exposure, are shown in italics. The relationship of these adverse events to isradipine administration is uncertain.
Musculoskeletal: cramps of legs/feet.
Respiratory: cough.
Cardiovascular: shortness of breath, hypotension, atrial fibrillation, ventricular fibrillation, myocardial infarction, heart failure.
Gastrointestinal: abdominal discomfort, constipation, diarrhea.
Urogenital: nocturia.
Nervous System: drowsiness, insomnia, lethargy, nervousness, impotence, decreased libido, depression, syncope, paresthesia (which includes numbness and tingling),transient ischemic attack, stroke.
Autonomic: hyperhidrosis, visual disturbance, dry mouth, numbness.
Miscellaneous: throat discomfort, leukopenia, elevated liver function tests.
Postmarketing Experience
FDA Package Insert for Isradipine contains no information regarding postmarketing experience.
Drug Interactions
Nitroglycerin: Isradipine has been safely coadministered with nitroglycerin.
Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of isradipine and hydrochlorothiazide does not result in altered pharmacokinetics of either drug. In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.
Propranolol: In a single dose study in normal volunteers, co-administration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability. Significant increases in AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study. However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d. propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug’s bioavailability. AUC and Cmax differences were <20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%). If isradipine therapy is initiated in a patient currently receiving cimetidine, careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
Rifampicin: In a study with healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits. If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
Warfarin: In a study with healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multiple-dose treatment with 5 mg b.i.d. isradipine. Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.
Digoxin: The concomitant administration of isradipine and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta-blocker and a calcium channel blocker. Even though such interactions have not been seen in clinical studies with isradipine, an increased volume of circulating fluids might be required if such an interaction were to occur.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): C Isradipine was administered orally to rats and rabbits during organogenesis. Treatment of pregnant rats with doses of 6, 20, or 60 mg/kg/day produced a significant reduction in maternal weight gain during treatment with the highest dose (150 times the maximum recommended human daily dose) but with no lasting effects on the mother or the offspring. Treatment of pregnant rabbits with doses of 1, 3, or 10 mg/kg/day (2.5, 7.5, and 25 times the maximum recommended human daily dose) produced decrements in maternal body weight gain and increased fetal resorption at the two higher doses. There was no evidence of embryotoxicity at doses which were not maternotoxic and no evidence of teratogenicity at any dose tested. In a peri/postnatal administration study in rats, reduced maternal body weight gain during late pregnancy at oral doses of 20 and 60 mg/kg/day isradipine was associated with reduced birth weights and decreased peri and postnatal pup survival.
There are no adequate and well controlled studies in pregnant women. The use of isradipine during pregnancy should only be considered if the potential benefit outweighs potential risks.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Isradipine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Isradipine during labor and delivery.
Nursing Mothers
It is not known whether isradipine is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for adverse effects of isradipine on nursing infants, a decision should be made as to whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatic Use
There is no FDA guidance on the use of Isradipine in geriatric settings.
Gender
There is no FDA guidance on the use of Isradipine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Isradipine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Isradipine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Isradipine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Isradipine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Isradipine in patients who are immunocompromised.
Administration and Monitoring
Administration
Oral
Monitoring
FDA Package Insert for Isradipine contains no information regarding drug monitoring .
IV Compatibility
FDA Package Insert for Isradipine contains no information regarding IV compatibility.
Overdosage
Minimal empirical data are available on isradipine overdosage. Three individual suicide attempts with dosages of isradipine reported to be from 20 mg up to 100 mg resulted in lethargy, sinus tachycardiaand, in the case of the person ingesting 100 mg, transient hypotension which responded to fluid therapy. A foreign report of the ingestion of 200 mg of isradipine with ethanol resulted only in flushing, tachycardiawith ST depression on ECG, and hypotension, all of which were reversible. The ingestion of 5 mg isradipine by a 22-month child and the accidental ingestion of 100 mg of isradipine by a 58-year old female did not result in any sequelae.
Available data suggest that, as with other dihydropyridines, overdosage with isradipine might result in excessive peripheral vasodilation with subsequent marked and probably prolonged systemic hypotension, and tachycardia. Emesis, gastric lavage, administration of activated charcoal followed in 30 minutes by a saline cathartic would be reasonable therapy. Isradipine is highly protein-bound and not removed by hemodialysis. Overdosage characterized by clinically significant hypotension should be treated with active cardiovascular support including monitoring of cardiac and respiratory function, elevation of lower extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor (such as epinephrine, norepinephrine, or levarterenol) may be helpful in restoring a normotensive state, provided that there is no contraindication to its use.
Refractory hypotension or AV conduction disturbances may be treated with intravenous calcium salts, or glucagon. Cimetidine should be withheld in such instances due to the risk of further increasing plasma isradipine levels.
Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival.
Pharmacology
![]() | |
Isradipine
| |
Systematic (IUPAC) name | |
3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | |
Identifiers | |
CAS number | |
ATC code | C08 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 371.387 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | 15-24% |
Protein binding | 95% |
Metabolism | 100% Hepatic |
Half life | 8 hours |
Excretion | 70% Renal, 30% Fecal |
Therapeutic considerations | |
Pregnancy cat. |
C |
Legal status |
POM(UK) [[Prescription drug|Template:Unicode-only]](US) |
Routes | Oral |
Mechanism of Action
Isradipine is a dihydropyridine calcium channel blocker. It binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and smooth muscle. The effects observed in mechanistic experiments in vitro and studied in intact animals and man are compatible with this mechanism of action and are typical of the class.
Except for diureticactivity, the mechanism of which is not clearly understood, the pharmacodynamic effects of isradipine observed in whole animals can also be explained by calcium channel blocking activity, especially dilating effects in arterioles which reduce systemic resistance and lower blood pressure, with a small increase in resting heart rate. Although like other dihydropyridine calcium channel blockers, isradipine has negative inotropic effects in vitro, studies conducted in intact anesthetized animals have shown that the vasodilating effect occurs at doses lower than those which affect contractility. In patients with normal ventricular function, isradipine’s afterload reducing properties lead to some increase in cardiac output.
Effects in patients with impaired ventricular function have not been fully studied.
Structure
Isradipine is a calcium antagonist available for oral administration in capsules containing 2.5 mg or 5 mg.
The structural formula of isradipine is:
![](/images/d/dd/Isradipine03.jpg)
Chemically, isradipine is 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester. Isradipine is a yellow, fine crystalline powder which is odorless or has a faint characteristic odor. Isradipine is practically insoluble in water (<10 mg/L at 37ºC), but is soluble in ethanol and freely soluble in acetone, chloroform and methylene chloride.
Active Ingredient: isradipine
Inactive Ingredients: colloidal silicon dioxide, red iron oxide (2.5 mg capsule only, yellow iron oxide, gelatin, anhydrous lactose, magnesium stearate, sodium lauryl sulfate, starch (corn), titanium dioxide, black ink: black iron oxide, shellac and potassium hydroxide.
Pharmacodynamics
In man, peripheral vasodilation produced by isradipine is reflected by decreased systemic vascular resistance and increased cardiac output. Hemodynamic studies conducted in patients with normal left ventricular function produced, following intravenous isradipine administration, increases in cardiac index, stroke volume index, coronary sinus blood flow, heart rate and peak positive left ventricular dP/dt. Systemic, coronary, and pulmonary vascular resistance was decreased. These studies were conducted with doses of isradipine which produced clinically significant decreases in blood pressure. The clinical consequences of these hemodynamic effects, if any, have not been evaluated.
Effects on heart rate are variable, dependent upon rate of administration and presence of underlying cardiac condition. While increases in both peak positive dP/dt and LV ejection fraction are seen when intravenous isradipine is given, it is impossible to conclude that these represent a positive inotropic effect due to simultaneous changes in preload and afterload. In patients with coronary artery disease undergoing atrial pacing during cardiac catheterization, intravenous isradipine diminished abnormalities of systolic performance. In patients with moderate left ventricular dysfunction, oral and intravenous isradipine in doses which reduce blood pressure by 12% to 30%, resulted in improvement in cardiac index without increase in heart rate, and with no change or reduction in pulmonary capillary wedge pressure. Combination of isradipine and propranolol did not significantly affect left ventricular dP/dt max. The clinical consequences of these effects have not been evaluated.
Pharmacokinetics
sradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%. Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5-20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration. Administration of isradipine with food significantly increases the time to peak by about an hour, but has no effect on the total bioavailability (area under the curve) of the drug. Isradipine is 95% bound to plasma proteins. Both peak plasma concentration and AUC exhibit a linear relationship to dose over the 0-20 mg dose range. The elimination of isradipine is biphasic with an early half-life of 1 ½-2 hours, and a terminal half-life of about 8 hours. The total body clearance of isradipine is 1.4 L/min and the apparent volume od disturbance is 3 L/kg.
Isradipine is completely metabolized prior to excretion, and no unchanged drug is detected in the urine. Six metabolites have been characterized in blood and urine, with the mono acids of the pyridine derivative and a cyclic lactone product accounting for >75% fo the material identified. Approximately 60%-65% of an administered dose is excreted in the urine and 25%-30% in the feces. Mild renal impairment (creatinine clearance 30 to 80 mL/min) increases the bioavailability (AUC) of isradipine by 45%. Progressive deterioration reverses this trend, and patients with severe renal failure (creatinine clearance <10 mL/min) who have been on hemodialysis show a 20% to 50% lower AUC than healthy volunteers. No pharmacokinetic information is available in drug therapy during hemodialysis. In elderly patients Cmax and AUC are increased by 13% and 40%, respectively; in patients with hepatic impairment, Cmax and AUC are increased by 32% and 52%, respectively.
Electrophysiologic Effects
In general, no detrimental effects on the cardiac conduction system were seen with the use of isradipine. Electrophysiologic studies were conducted on patients with normal sinus and atrioventricular node function. Intravenous isradipine in doses which reduce systolic blood pressure did not affect PR, QRS, AH* or HV* intervals.
No changes were seen in Wenckebach cycle length, atrial, and ventricular refractory periods. Slight prolongation of QTc interval of 3% was seen in one study. Effects on sinus node recovery time (CSNRT) were mild or not seen.
In patients with sick sinus syndrome, at doses which significantly reduced blood pressure, intravenous isradipine resulted in no depressant effect on sinus and atrioventricular node function.
- AH = conduction time from low right atrium to His bundle deflection, or AV nodal conduction time; HV = conduction time through His bundle and the bundle branch-Purkinje system.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Treatment of male rats for 2 years with 2.5, 12.5, or 62.5 mg/kg/day isradipine admixed with the diet (approximately 6, 31, and 156 times the maximum recommended daily dose based on a 50 kg man) resulted in dose dependent increases in the incidence of benign Leydig cell tumors and testicular hyperplasiarelative to untreated control animals. These findings, which were replicated in a subsequent experiment, may have been indirectly related to an effect of isradipine on circulating gonadotropin levels in the rats; a comparable endocrine effect was not evident in male patients receiving therapeutic doses of the drug on a chronic basis. Treatment of mice for two years with 2.5, 15, or 80 mg/kg/day isradipine in the diet (approximately 6, 38, and 200 times the maximum recommended dose based on a 50 kg man) showed no evidence of oncogenicity. There was no evidence of mutagenic potential based on the results of a battery of mutagenic tests. No effect on fertility was observed in male and female rats treated with up to 60 mg/kg/day isradipine.
Clinical Studies
FDA Package Insert for Isradipine contains no information regarding clinical studies.
How Supplied
Isradipine Capsules, USP 2.5 mg are Filled Gelatin Capsules Size #3, Cap: White Opaque/Body: White Opaque with Imprint "A-263" on cap and body. Available in bottles of 100's and 500's. Isradipine Capsules, USP 5 mg are Filled Gelatin Capsules Size #3, Cap: Flesh Opaque/Body: Flesh Opaque with Imprint "A-264" on cap and body. Available in bottles of 100's and 500's.
Storage
Store 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure as required.
Images
Drug Images
{{#ask: Page Name::Isradipine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
![](/images/6/60/Isradipine_label_01.jpg)
![](/images/3/30/Isradipine_label_02.jpg)
![](/images/2/2b/Isradipine_label_03.jpg)
![](/images/1/18/Isradipine_label_04.jpg)
![](/images/4/42/Isradipine_panel_01.png)
![](/images/1/12/Isradipine_panel_02.png)
{{#ask: Label Page::Isradipine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
FDA Package Insert for Isradipine contains no information regarding Patient Counseling Information.
Precautions with Alcohol
Alcohol-Isradipine sandbox interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Dynacirc
- Dynacirc CR
Look-Alike Drug Names
Dynacirc - Dynacin[3]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Taylor SH, Jackson NC, Allen J, Pool PE (1987). "Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris". Am J Cardiol. 59 (3): 123B–129B. PMID 2949583.
- ↑ Rüegg PC, Nelson DJ (1989). "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris". Am J Med. 86 (4A): 70–4. PMID 2565689.
- ↑ "https://www.ismp.org". External link in
|title=
(help)